Another Nvidia (NVDA)-backed company is on its way to the stock market. Iambic Therapeutics, an AI-driven drug discovery firm, has filed to go public on the Nasdaq under the ticker IAM. Renaissance Capital estimates the IPO could raise up to $100 million. The Nvidia name will draw attention, but the real question is whether the company underneath is worth owning.
What Iambic Actually Does
Iambic uses artificial intelligence to design new medicines. Its platform runs on two AI models. The first is called Enchant, which predicts how a drug candidate will behave in the body before it’s ever made. The second model is NeuralPLexer, which predicts the 3D structure of proteins and how drug molecules bind to them. These feed a robotic lab that makes and tests compounds every week, then feeds the results back to improve the AI. It’s a loop that gets smarter with each cycle.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
The whole system is built for speed. Iambic’s lead drug went from the start of the program to its first human dose in under two years. The industry usually takes four years or more. In a field where AI drug discovery has produced more promises than results, moving that fast is a genuine edge.
But Speed Means Little Without Results
This is where Iambic stands apart from most of its peers. Plenty of companies claim their AI can design drugs faster. Far fewer have taken one into patients and seen it actually work against cancer. Iambic has. The drug targets HER2, a protein behind several cancers, and is built to reach tumors in the brain that many existing treatments can’t. In its early trial, IAM1363 shrank tumors in about 28% of patients with measurable disease, including some who had run out of other options. It even showed activity in cancers with no approved HER2 drugs. For an early-stage trial in heavily treated patients, that’s an encouraging signal. Iambic plans to begin a registrational trial, the kind that can lead to approval, as early as 2027. Two more drugs sit behind it, with Iambic planning to file IND applications for both in the fourth quarter, followed by human trials after regulatory clearance.
Why the Big Names Are Involved
Iambic has raised about $462 million so far, from Nvidia, the Qatar Investment Authority, Coatue, and others. It also runs research collaborations with a striking list of drugmakers, including AbbVie (ABBV), Takeda (TAK), Bayer (BAYRY), Jazz Pharmaceuticals (JAZZ), and Revolution Medicines (RVMD). These partners use Iambic’s platform on their own drug targets, which both validates the technology and brings in revenue that doesn’t depend on any single drug succeeding.
Nvidia’s involvement makes sense beyond the money. AI drug discovery runs on exactly the kind of heavy computing Nvidia sells, so Iambic is both an investment and a showcase for AI-driven science.
Should You Buy Iambic?
The appeal is real, but so is the risk. Iambic is a clinical-stage biotech with no approved products, and its revenue still comes from partnerships rather than from selling drugs. It's also burning cash fast, with losses widening to $77 million last year and $50 million in the first half of 2026 alone. The company’s value rests heavily on IAM1363 succeeding in larger trials, where many promising early drugs fail. The platform and the partnerships soften that risk, but a HER2 drug still has to prove itself against established rivals.
Nonetheless, for investors who believe AI will genuinely speed up drug discovery, I think Iambic is one of the more credible ways to bet on the field. Even though it's in early stages, it already has real clinical data behind the story rather than just a platform. Just know you’re buying a high-risk biotech, and the science still has to deliver.
On the date of publication, Jabran Kundi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
This Cancer Drug Is Already Working. Now Its Nvidia-Backed Maker Is Going Public: Here’s What You Need to Know About Its IPO BlackRock’s CEO Is Backing a $1.5 Trillion Social Security Fund That Needs 75 Years to Work. CBO Projects the Trust Fund Runs Short In 2032. Employment, GDP and Other Key Things to Watch this Week This Photonics Company Trades at 2x Its Cash. Here’s What It Does, and Whether You Should Buy It.